News

GMP-validated MS-based residual enzyme analysis

May 14 2024

Alphalyse has performed the world’s first GMP-validated mass spectrometry-based residual enzyme analysis

Enzyme-assisted process steps are sometimes part of the manufacturing of new recombinant protein drugs.

According to ICH guidelines, safety and quality risk management must be employed to prevent process-added enzymes from co-purifying with the final drug product. However, suitable ELISAs may not exist to demonstrate the clearance of these specific enzymes.

In collaboration with 89bio, a biotech developer of therapies for liver and cardiometabolic diseases, Alphalyse has developed and validated an LC-MS-based assay with a low-to-sub ppm detection limit.

The assay enables reliable and reproducible identification and quantification of specific residual enzymes by targeted LC-MS using Multiple Reaction Monitoring (MRM) technology.

The analysis is performed according to GMP standards, making it fit for batch-release testing.

quality-system-certification-GMP-icon

Talk to us

Whatever protein-related challenge or question you may have, we would love to help. Our experts can help you decide on the best analytical approach for your project by email or online meeting - providing advice without obligation.

I would like an
Hidden
Hidden
Hidden
This field is for validation purposes and should be left unchanged.